Related Experiment Video

Updated: Feb 27, 2026

Investigation of Beige Fat Biology and Metabolism Using the CRISPR SunTag-p65-HSF1 Activation System
09:52

Investigation of Beige Fat Biology and Metabolism Using the CRISPR SunTag-p65-HSF1 Activation System

Published on: January 6, 2023

2.9K

Advances on PPARγ Research in the Emerging Era of Precision Medicine

Pinyi Lu1, Zhongming Zhao1,2

  • 1Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, United States.

Current Drug Targets
|June 24, 2017
PubMed
Abstract

Insights

Peroxisome proliferator-activated receptor gamma (PPARγ) plays a key role in metabolism and diabetes. Understanding its regulation is crucial for developing safer type 2 diabetes treatments with fewer side effects.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Pharmacology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor regulating glucose and lipid metabolism.
  • Thiazolidinediones (TZDs) activate PPARγ, improving insulin sensitivity and beta cell function in type 2 diabetes (T2D).
  • TZDs have been widely used for T2D since 1997 despite significant adverse effects.

Purpose of the Study:

  • To review the mechanisms of action and multilayer regulations of PPARγ.
  • To explore novel PPARγ-modulating therapeutics with improved safety profiles.
  • To highlight research on genetic variants influencing PPARγ function and drug response.

Main Methods:

  • Systematic literature review of PPARγ mechanisms and regulation.
  • Analysis of existing and emerging PPARγ-targeting therapies.
  • Examination of genetic factors affecting PPARγ activity and therapeutic outcomes.

Main Results:

  • Detailed overview of PPARγ's diverse regulatory pathways.
  • Identification of potential therapeutic strategies to mitigate TZD-associated adverse effects.
  • Emphasis on the role of genetic variations in personalized diabetes treatment.

Conclusions:

  • PPARγ is a critical target for T2D management.
  • Further research into PPARγ regulation and genetic influences can lead to safer, precision medicine approaches.
  • Development of novel PPARγ modulators is essential for overcoming current therapeutic limitations.
Keywords:
Peroxisome proliferator-activated receptor gammamechanism of action and regulationnovel therapeuticsprecision medicinethiazolidinedionetype 2 diabetes.

More Related Videos

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

39.6K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
74
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
63
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54